Page 1 of 1

Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Posted: Sun Jun 16, 2019 6:49 pm
by huntingonthebluffs
FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

https://library.ehaweb.org/eha/2019/24t ... imetelstat

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Posted: Sun Jun 16, 2019 7:58 pm
by Ryan
Thanks for posting.

The statistical superiority of Imetelstat is not only clear but profound.

We’re talking about over a year-and-a-half of continued life, that most key of KPI metrics.

It’s not if but when Imetelstat is approved on this indication, and I suppose the when is early next year but even that seems too far away.

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Posted: Sun Jun 16, 2019 8:55 pm
by Ryan
PS - 65% lower risk of death

Imetelstat is superior to Best Available Therapy for R/R patients in MF, that can be stated unequivocally.

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Posted: Mon Jun 17, 2019 6:14 pm
by huntingonthebluffs
For completeness, here are the links to the Geron 6/17/19 press release and the IMBark poster presentation. Note that the poster presentation link from my initial posts may be more usable as the various sections will enlarge when clicked on.

http://ir.geron.com/news-releases/news- ... s-european

https://www.geron.com/file.cfm/53/docs/ ... 0FINAL.pdf